Equitec Proprietary Markets’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Equitec Proprietary Markets’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$2.83M	Buy	+122,800	New	+$1.56M	0.74%	17

Other funds holding PRVL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Equitec Proprietary Markets's PRVL Position: Q4 2020 in Review

Equitec Proprietary Markets opened a new position in Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020: 122,800 shares worth $2.83M. The stake represents 0.74% of the portfolio and ranks #17 among its holdings.

93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

Equitec Proprietary Markets held 122,800 shares of Prevail Therapeutics Inc. Common Stock worth $2.83M as of Q4 2020.
Prevail Therapeutics Inc. Common Stock was a new Equitec Proprietary Markets position in Q4 2020.
Prevail Therapeutics Inc. Common Stock made up 0.74% of Equitec Proprietary Markets's portfolio in Q4 2020, its #17 holding.
93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Equitec Proprietary Markets's 13F filing for Q4 2020, filed 26 Jan 2021.